Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Digital tirzepatide care study
A UK study of 8,127 women reported six-month outcomes from a structured digital programme where 99.8% started tirzepatide.
What Exit Interviews Add to GLP-1 Trials
A study from ACHIEVE-3 shows what exit interviews can add to oral GLP-1 trial results, and what they cannot answer.
GLP-1 Drugs and Alzheimer's: The Evidence
A 2026 meta-analysis found no cognitive or functional benefit from GLP-1 receptor agonists in Alzheimer's disease or mild cognitive impairment.
GLP-1 and GIP Obesity Drugs: Evidence
A source-led guide to the evidence, safety limits, and unanswered questions around GLP-1 and dual GIP/GLP-1 obesity medicines.
Why Weight Loss Can Slow on Tirzepatide
A slower scale trend on tirzepatide can have several meanings. Here is what trials show, what the scale misses, and when to seek clinical review.
Semaglutide vs Liraglutide: Study Results
A real-world study compared semaglutide and liraglutide for later diabetes and cardiovascular outcomes, with important limits.
GLP-1 drugs and addiction evidence
A 2026 review found early GLP-1 and semaglutide signals in substance use disorders, but randomized evidence remains limited and mixed.
Weight Loss and Sleep-Disordered Breathing
A 2026 review explains how weight management, tirzepatide and positive airway pressure fit into care for obesity-related sleep breathing disorders.
Semaglutide and Ischemic Colitis
A 2026 oral semaglutide case report describes ischemic colitis recurring after rechallenge, a stronger signal that still cannot prove general risk.
How drug promotion shapes prescribing
A 2026 Cochrane review links pharmaceutical promotion with prescribing quality, quantity, and cost, with important limits on causality.
Semaglutide plus dapagliflozin in CKD
A short retrospective study compared semaglutide, dapagliflozin, and their combination in type 2 diabetes with chronic kidney disease.
BPC-157 and TB-500 for tendon tears
Why an online BPC-157 or TB-500 protocol cannot establish tendon healing when controlled human evidence and safety data are missing.